GalNAc-Conjugated Antisense Oligonucleotides for Hepatocyte Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antisense compounds face challenges in efficiently delivering and maintaining activity in liver cells, particularly hepatocytes, due to issues with conjugate interference and clearance, leading to suboptimal potency and tolerability.
Innovation Solution
Conjugated antisense compounds with cleavable moieties, such as GalNAc clusters, are attached to the 5' end of single-stranded antisense oligonucleotides, enhancing uptake and activity in liver cells by ensuring timely release of the active form through endogenous nucleases, while maintaining tolerability and reducing kidney exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conjugated antisense compounds are used to enhance liver cell uptake, then delivery efficiency to hepatocytes is improved, but kidney exposure increases leading to reduced tolerability
Solution Approach 1:
The compound is segmented into distinct functional regions: a liver-targeting conjugate portion (GalNAc clusters) attached to an antisense oligonucleotide portion. This segmentation allows the liver-targeting moiety to direct uptake in hepatocytes while the antisense portion maintains sequence-specific activity, and the kidney can be spared by optimizing the conjugate structure to favor hepatic clearance pathways
Solution Approach 2:
The GalNAc conjugate acts as an intermediary that mediates selective delivery to the liver by binding to asialoglycoprotein receptors on hepatocytes. This intermediary structure enables the antisense compound to reach its target in the liver while the conjugate itself can be designed to minimize kidney accumulation through appropriate molecular weight and structural characteristics
2Duration of action of stationary object
If stable conjugates are used to maintain activity, then duration of action is improved, but conjugate interference prevents timely release of active form
Solution Approach 1:
The conjugate design incorporates dynamic characteristics where the stability of the conjugate is optimized to maintain integrity during circulation and delivery, while intracellular conditions (such as enzymatic environments or pH changes) trigger controlled release of the active antisense form. This dynamic behavior ensures both sustained presence in the body and timely activation at the target site
Solution Approach 2:
The conjugate is designed with preliminary stabilization features that protect the antisense compound during delivery, while pre-programmed release mechanisms (such as cleavable linkers or enzyme-sensitive bonds) are built in advance to ensure timely release of the active form once inside the target cell, balancing stability with eventual activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugated antisense compounds demonstrate improved potency and delivery to hepatocytes, with reduced kidney exposure and minimal immunogenicity, offering enhanced therapeutic potential.
Implementation Method 1
an antisense compound hybridizes to a target nucleic acid and modulates the amount, activity, and/or function of the target nucleic acid
Implementation Method 2
target mRNA degradation or occupancy-based inhibition. An example of modulation of RNA target function by degradation is RNase H-based degradation of the target RNA upon hybridization with a DNA-like antisense compound
Implementation Method 3
enhancing uptake and activity in liver cells by ensuring timely release of the active form through endogenous nucleases
Data Source
AI summary
Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.